Skip to main content

Advertisement

SpringerLink
Log in

A consensus statement regarding the utilization of BMP in spine surgery

  • Spine: BMP (K Singh, Section Editor)
  • Published:
Current Reviews in Musculoskeletal Medicine Aims and scope Submit manuscript

Abstract

Recombinant human bone morphogenetic protein - 2 (rh-BMP-2) was first approved by the United States Food and Drug Administration (FDA) in 2002 for use in anterior lumbar interbody fusions. Since that time, it has been estimated that “off label” use accounts for 85 % of applications. Original, industry sponsored studies demonstrated superior fusion rates with decreased incidence of complications when compared with traditional iliac crest bone graft. These studies have been criticized for potential bias and newer research has detailed potential complications as well as alternative applications. Potential off label uses of rhBMP-2 include: anterior lumbar fusions, single level posterior lumbar fusions, multiple level posterior lumbar fusions, posterior cervical fusions, long deformity fusions, in the presence of vertebral osteomyelitis, and in patients with history of malignancy. A review of the literature related to rhBMP-2 was conducted to evaluate its use for the above-mentioned applications with a special focus on fusion rates, observed complications, and clinical or radiographic outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. United States Food and Drug Administration Website.

  2. Hsu WK, Nickoli MS, Wang JC, et al. Improving the clinical evidence of bone graft substitute technology in lumbar spine surgery. Glob Spine J. 2012;2:239–48.

    Article  Google Scholar 

  3. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech. 2002;15:337–49.

    Article  PubMed  Google Scholar 

  4. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderston RA. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine. 2002;27:2396–408.

    Article  PubMed  Google Scholar 

  5. Haid Jr RW, Branch Jr CL, Alexander JT, Burkus JK. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004;4:527–38. discussion 538–529.

    Article  PubMed  Google Scholar 

  6. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11:471–91. Represents a study critical of past research pertaining to rhBMP-2. Raises concerns of safety and side effects.

    Article  PubMed  Google Scholar 

  7. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158:890–902. Results from YODA study. Demonstrated similar clinical outcomes of rhBMP-2 and iliac crest bone graft.

    Article  PubMed  Google Scholar 

  8. Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med. 2013;158:877–89. Results from the Yale University Open Access Data Project (YODA). Demonstrating increased radiographic fusions, and clinically insignificant differences in patient outcomes. Results inconclusive for increased cancer risk.

    Article  PubMed  Google Scholar 

  9. Burkus JK, Sandhu HS, Gornet MF. Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft. Spine. 2006;31:775–81.

    Article  PubMed  Google Scholar 

  10. Burkus JK, Gornet MF, Schuler TC, Kleeman TJ, Zdeblick TA. Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2. J Bone Joint Surg Am. 2009;91:1181–9.

    Article  PubMed  Google Scholar 

  11. Tepper G, Rabbani R, Yousefzadeh M, Prince D. Quantitative assessment of retrograde ejaculation using semen analysis, comparison with a standardized qualitative questionnaire, and investigating the impact of rhBMP-2. Spine. 2013;38:841–5.

    Article  PubMed  Google Scholar 

  12. Deutsch H. High-dose bone morphogenetic protein-induced ectopic abdomen bone growth. Spine J. 2010;10:e1–4.

    Article  PubMed  Google Scholar 

  13. Lykissas MG, Aichmair A, Sama AA, et al. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study. Spine J. 2014;14:217–24.

    Article  PubMed  Google Scholar 

  14. Pimenta L, Marchi L, Oliveira L, Coutinho E, Amaral R. A prospective, randomized, controlled trial comparing radiographic and clinical outcomes between stand-alone lateral interbody lumbar fusion with either silicate calcium phosphate or rh-BMP2. J Neurol Surg A Cent Eur Neurosurg. 2013;74:343–50.

    PubMed  Google Scholar 

  15. Hughes AP, Taher F, Farshad M, Aichmair A. Multiple myeloma exacerbation following utilization of bone morphogenetic protein-2 in lateral lumbar interbody fusion: a case report and review of the literature. Spine J. 2014;14:e13–9.

  16. Taher F, Lebl DR, Hughes AP, Girardi FP. Contralateral psoas seroma after transpsoas lumbar interbody fusion with bone morphogenetic protein-2 implantation. Spine J. 2013;13:e1–5.

    Article  PubMed  Google Scholar 

  17. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine. 2002;27:2662–73.

    Article  PubMed  Google Scholar 

  18. Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix vs iliac crest bone graft. Spine. 2006;31:2534–9. discussion 2540.

    Article  PubMed  Google Scholar 

  19. Dimar II JR, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am. 2009;91:1377–86.

    Article  PubMed  Google Scholar 

  20. Glassman SD, Dimar III JR, Burkus K, et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine. 2007;32:1693–8.

    Article  PubMed  Google Scholar 

  21. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J. 2009;9:623–9.

    Article  PubMed  Google Scholar 

  22. Michielsen J, Sys J, Rigaux A, Bertrand C. The effect of recombinant human bone morphogenetic protein-2 in single-level posterior lumbar interbody arthrodesis. J Bone Joint Surg Am. 2013;95:873–80.

    Article  CAS  PubMed  Google Scholar 

  23. Mroz TE, Wang JC, Hashimoto R, Norvell DC. Complications related to osteobiologics use in spine surgery: a systematic review. Spine. 2010;35(9 Suppl):S86–104.

    Article  PubMed  Google Scholar 

  24. Crandall DG, Revella J, Patterson J, Huish E, Chang M, McLemore R. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease—part 1: large series diagnosis related outcomes and complications with 2- to 9-year follow-up. Spine. 2013;38:1128–36.

    Article  PubMed  Google Scholar 

  25. Crandall DG, Revella J, Patterson J, Huish E, Chang M, McLemore R. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease—part 2: BMP dosage-related complications and long-term outcomes in 509 patients. Spine. 2013;38:1137–45.

    Article  PubMed  Google Scholar 

  26. Hoffmann MF, Jones CB, Sietsema DL. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report. Spine J. 2013;13:1244–52.

    Article  PubMed  Google Scholar 

  27. Hamilton DK, Jones-Quaidoo SM, Sansur C, Shaffrey CI, Oskouian R, Jane Sr JA. Outcomes of bone morphogenetic protein-2 in mature adults: posterolateral non-instrument-assisted lumbar decompression and fusion. Surg Neurol. 2008;69:457–61. discussion 461–452.

    Article  PubMed  Google Scholar 

  28. Lee KB, Taghavi CE, Hsu MS, et al. The efficacy of rhBMP-2 vs autograft for posterolateral lumbar spine fusion in elderly patients. Eur Spine J. 2010;19:924–30.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Deyo RA, Ching A, Matsen L, et al. Use of bone morphogenetic proteins in spinal fusion surgery for older adults with lumbar stenosis: trends, complications, repeat surgery, and charges. Spine. 2012;37:222–30.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Hoffmann MF, Jones CB, Sietsema DL. Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderly. J Orthop Surg Res. 2013;8:1.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Perri B, Cooper M, Lauryssen C, Anand N. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. Spine J. 2007;7:235–9.

    Article  PubMed  Google Scholar 

  32. Buttermann GR. Prospective nonrandomized comparison of an allograft with bone morphogenic protein vs an iliac-crest autograft in anterior cervical discectomy and fusion. Spine J. 2008;8:426–35.

    Article  PubMed  Google Scholar 

  33. Fineberg SJ, Ahmadinia K, Oglesby M, Patel AA, Singh K. Hospital outcomes and complications of anterior and posterior cervical fusion with bone morphogenetic protein. Spine. 2013;38:1304–9.

    Article  PubMed  Google Scholar 

  34. Hodges SD, Eck JC, Newton D. Retrospective study of posterior cervical fusions with rhBMP-2. Orthopedics. 2012;35:e895–8.

    Article  PubMed  Google Scholar 

  35. Dorward IG, Buchowski JM, Stoker GE, Zebala LP. Posterior cervical fusion with recombinant human bone morphogenetic protein-2: complications and fusion rate at minimum two-year follow-up. J Spinal Disord Tech. 2013. doi:10.1097/BSD.0b013e318286fa7e.

  36. Crawford III CH, Carreon LY, McGinnis MD, Campbell MJ, Glassman SD. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge vs iliac crest bone graft for posterior cervical arthrodesis. Spine. 2009;34:1390–4.

    Article  PubMed  Google Scholar 

  37. Cahill KS, Chi JH, Day A, Claus EB. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 2009;302:58–66.

    Article  CAS  PubMed  Google Scholar 

  38. Hiremath GK, Steinmetz MP, Krishnaney AA. Is it safe to use recombinant human bone morphogenetic protein in posterior cervical fusion? Spine. 2009;34:885–9.

    Article  PubMed  Google Scholar 

  39. Mulconrey DS, Bridwell KH, Flynn J, Cronen GA, Rose PS. Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion. Spine. 2008;33:2153–9.

    Article  PubMed  Google Scholar 

  40. Kim HJ, Buchowski JM, Zebala LP, Dickson DD, Koester L, Bridwell KH. RhBMP-2 is superior to iliac crest bone graft for long fusions to the sacrum in adult spinal deformity: four- to 14-year follow-up. Spine. 2013;38:1209–15.

    Article  PubMed  Google Scholar 

  41. Maeda T, Buchowski JM, Kim YJ, Mishiro T, Bridwell KH. Long adult spinal deformity fusion to the sacrum using rhBMP-2 vs autogenous iliac crest bone graft. Spine. 2009;34:2205–12.

    Article  PubMed  Google Scholar 

  42. Bess SL, Line BG, Lafage V, et al. International Spine Study Group ISSG. Does recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) use in adult spinal deformity (ASD) increase complications and are complications associated with location of rhBMP-2 use?: a prospective, multicenter study of 279 consecutive patients. Spine. 2013.

  43. Mesfin A, Buchowski JM, Zebala LP, et al. High-dose rhBMP-2 for adults: major and minor complications: a study of 502 spine cases. J Bone Joint Surg Am. 2013;95:1546–53.

    Article  PubMed  Google Scholar 

  44. Rahman RK, Buchowski JM, Stephens B, Dorward IG, Koester LA, Bridwell KH. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose At L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity. Spine. 2013;38:2264–71.

    Article  PubMed  Google Scholar 

  45. Miller CP, Simpson AK, Whang PG, et al. Effects of recombinant human bone morphogenetic protein 2 on surgical infections in a rabbit posterolateral lumbar fusion model. Am J Orthop. 2009;38:578–84.

    PubMed  Google Scholar 

  46. O’Shaughnessy BA, Kuklo TR, Ondra SL. Surgical treatment of vertebral osteomyelitis with recombinant human bone morphogenetic protein-2. Spine. 2008;33:E132–9.

    Article  PubMed  Google Scholar 

  47. Allen RT, Lee YP, Stimson E, Garfin SR. Bone morphogenetic protein-2 (BMP-2) in the treatment of pyogenic vertebral osteomyelitis. Spine. 2007;32:2996–3006.

    Article  PubMed  Google Scholar 

  48. Aryan HE, Lu DC, Acosta Jr FL, Ames CP. Corpectomy followed by the placement of instrumentation with titanium cages and recombinant human bone morphogenetic protein-2 for vertebral osteomyelitis. J Neurosurg Spine. 2007;6:23–30.

    Article  PubMed  Google Scholar 

  49. Holtzhausen A, Golzio C, How T, et al. Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J. 2014;28:1248–67.

  50. Kokorina NA, Zakharkin SO, Krebsbach PH, Nussenbaum B. Treatment effects of rhBMP-2 on invasiveness of oral carcinoma cell lines. Laryngoscope. 2011;121:1876–80.

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Rici RE, Alcantara D, Fratini P, et al. Mesenchymal stem cells with rhBMP-2 inhibits the growth of canine osteosarcoma cells. BMC Vet Res. 2012;8:17.

    Article  CAS  PubMed  Google Scholar 

  52. Carragee EJ, Chu G, Rohatgi R, et al. Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am. 2013;95:1537–45.

    Article  PubMed  Google Scholar 

  53. Mines D, Gu Y, Kou TD, Cooper GS. Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2011;20:111–8.

    Article  PubMed  Google Scholar 

  54. Garulli C, Kalogris C, Pietrella L, et al. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling. Cell Signal. 2014;26:352–62.

    Article  CAS  PubMed  Google Scholar 

  55. Boeuf S, Bovee JV, Lehner B, et al. BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors. BMC Cancer. 2012;12:488.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Orui H, Imaizumi S, Ogino T, Motoyama T. Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: a preliminary report. J Orthop Sci. 2000;5:600–4.

    Article  CAS  PubMed  Google Scholar 

  57. Sotobori T, Ueda T, Myoui A, et al. Bone morphogenetic protein-2 promotes the haptotactic migration of murine osteoblastic and osteosarcoma cells by enhancing incorporation of integrin beta1 into lipid rafts. Exp Cell Res. 2006;312:3927–38.

    Article  CAS  PubMed  Google Scholar 

  58. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine. 2000;25:376–81.

    Article  CAS  PubMed  Google Scholar 

  59. Slosar PJ, Josey R, Reynolds J. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes. Spine J. 2007;7:301–7.

    Article  PubMed  Google Scholar 

  60. Hamilton DK, Smith JS, Reames DL, Williams BJ, Chernavvsky DR, Shaffrey CI. Safety, efficacy, and dosing of recombinant human bone morphogenetic protein-2 for posterior cervical and cervicothoracic instrumented fusion with a minimum 2-year follow-up. Neurosurgery. 2011;69:103–11. discussion 111.

    Article  PubMed  Google Scholar 

  61. Dagostino PR, Whitmore RG, Smith GA, Maltenfort MG, Ratliff JK. Impact of bone morphogenetic proteins on frequency of revision surgery, use of autograft bone, and total hospital charges in surgery for lumbar degenerative disease: review of the Nationwide Inpatient Sample from 2002 to 2008. Spine J. 2014;14:20–30. Examines cost and re-operation rates in patients receiving rhBMP-2. Demonstrated that BMP-2 use has led to higher hospital charges.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Brett Walker, John Koerner, and Sriram Sankarayanaryanan declare that they have no conflict of interest. Kris Radcliff has been a consultant for and has received royalties from Globus Medical, has received honoraria from Depuy, and has received travel/accommodations expenses covered or reimbursed from Depuy, Globus, Medtronic, Relievant, and Stryker.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Michigan State University, McLaren Oakland, Pontiac, MI, USA

    Brett Walker

  2. 1015 Walnut St, Room 508, Philadelphia, PA, 19107, USA

    John Koerner

  3. Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA

    Sriram Sankarayanaryanan

  4. Rothman Institute, Department of Orthopedic Surgery, Thomas Jefferson University, 925 Chestnut, Philadelphia, PA, 19107, USA

    Kris Radcliff

Authors
  1. Brett Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Koerner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sriram Sankarayanaryanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kris Radcliff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kris Radcliff.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walker, B., Koerner, J., Sankarayanaryanan, S. et al. A consensus statement regarding the utilization of BMP in spine surgery. Curr Rev Musculoskelet Med 7, 208–219 (2014). https://doi.org/10.1007/s12178-014-9224-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12178-014-9224-0

Keywords

Search

Navigation